

KETABEL 100 MG/ML SOLUTION FOR INJECTION

Authorised

- Ketamine hydrochloride

Product identification

Medicine name:

KETABEL 100 MG/ML SOLUTION FOR INJECTION

Ketabel 100 mg/ml oldatos injekció kutyák, macskák, szarvasmarhák, juhok, kecskék, lovak, sertések és laboratóriumi állá

Active substance:

Ketamine hydrochloride

Target species:

Cattle

Pig

Rat

Guinea pig

Rabbit

Cat

Sheep

Goat

Dog

Horse

Hamster

Mouse

Route of administration:

Intramuscular use

Intravenous use

Intraperitoneal use

Product details

Active substance and strength:

Ketamine hydrochloride

115.34 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:**Intramuscular use:**

-

Cattle

- Meat and offal. 1 day

- Milk. 0 day

-

Pig

- Meat and offal. 1 day

-

Sheep

- Meat and offal. 1 day

- Milk. 0 day

-

Goat

- Meat and offal. 1 day

- Milk. 0 day

Intravenous use:

-

Cattle

- Meat and offal. 1 day
- Milk. 0 day

-

Horse

- Meat and offal. 1 day
- Milk. 0 day

-

Sheep

- Meat and offal. 1 day
- Milk. 0 day

-

Goat

- Meat and offal. 1 day
- Milk. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN01AX03

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Hungary

Available in:

Hungary

Package description:

Carton with 1 vial of 10 mL

Carton with 10 vials of 25 mL

Carton with 1 vial of 25 mL
Carton with 10 vials of 10 mL

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Bela-Pharm GmbH & Co. KG

Marketing authorisation date:

2/07/2020

Manufacturing sites for batch release:

Bela-Pharm GmbH & Co. KG

Responsible authority:

Directorate Of Veterinary Medicinal Products

Authorisation number:

4192/X/20 NÉBIH ÁTI

Date of authorisation status change:

2/07/2020

Reference member state:

France

Procedure number:

FR/V/0338/001

Concerned member states:

Austria Belgium Bulgaria Cyprus Czechia Denmark Estonia Finland
Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Netherlands Norway Portugal Romania Slovakia Slovenia Spain

Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet